Results of two worldwide surveys into physician awareness and perceptions of extended-spectrum β-lactamases

被引：4

作者：

Goossens, H

Malhotra-Kumar, S

Eraksoy, H

Unal, S

Grabein, B

Masterton, R

Mendes, C

Garcia-Rodriguez, JA

Russo, G

Jones, RN

机构：

[1] Univ Hosp, Dept Microbiol, B-2650 Edegem, Belgium

[2] Istanbul Univ, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey

[3] Hacettepe Univ, Dept Internal Med, Ankara, Turkey

[4] Max Von Pettenkofer Inst, D-8000 Munich, Germany

[5] Crosshouse Hosp, Ayrshire & Arran Acute Hosp NHS Trust, Kilmarnock, Scotland

[6] Fleury Med Diagnost Ctr, Sao Paulo, Brazil

[7] Univ Hosp Salamanca, Dept Microbiol, Salamanca, Spain

[8] Univ Catania, Dept Microbial Sci, I-95124 Catania, Italy

[9] Jones Grp JMI Labs, N Liberty, IA USA

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2004年 / 10卷 / 08期

关键词：

ESBLs; Escherichia coli; Klebsiella pneumoniae; meropenem; MYSTIC; susceptibility testing;

D O I：

10.1111/j.1469-0691.2004.00957.x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

An omnibus survey of microbiologists (n = 400) and a survey of participants (n = 49) in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme were conducted to determine the awareness and prevalence of extended-spectrum beta-lactamases (ESBLs), and the regularity and method of screening. Of the omnibus survey participants, 69% screened regularly for ESBLs, compared with 83% of MYSTIC participants. In both surveys, ESBLs were more common in Klebsiella pneumoniae (73% and 79%, respectively) and Escherichia coli (63% and 81%, respectively) than in other bacteria. The surveys demonstrated that awareness of, and testing for, ESBLs is inconsistent.

引用

页码：760 / 762

页数：3

共 7 条

[1]

Bush K, 2001, CLIN INFECT DIS, V32, P1085, DOI 10.1086/319610

[2]

Felmingham D, 1996, J ANTIMICROB CHEMOTH, V38, P1

[3] Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae:: Risk factors for infection and impact of resistance on outcomes [J].